患者个体化Panel覆盖的位点数量由方法学设定,常见的个体化Panel监测MRD选择监测16个或更多的突变。而固定化Panel 监测MRD的突变数量在不同患者中存在较大差异,不同癌种患者突变图谱存在较大差异,相同癌种不同患者间突变同样存在异质性,CAPP-seq技术采用肺癌Panel,平均每位患者检测到4个突变[1]。综合对比,我们不难发...
分析显示NGS-MRD检测阳性的患者具有显著更高的3年累积复发风险(CIR,HR = 2.24 [1.12, 5.30],P = 0.02)和更差的生存率(HR = 3.17 [1.07, 9.37],P = 0.03)。在MPFC-MRD检测阴性的患者中,NGS-MRD检测阳性的患者具有显著更高的3年CIR(HR = 2.64 [1.12, 6.21],P = 0.02)和更差的生存率(HR = 3.81 ...
而固定化Panel 监测MRD的突变数量在不同患者中存在较大差异,不同癌种患者突变图谱存在较大差异,相同癌种不同患者间突变同样存在异质性,CAPP-seq技术采用肺癌Panel,平均每位患者检测到4个突变[1]。综合对比,我们不难发现个体化Panel监测的突变数量往往会优于固定化Panel,而监测的突变数量可能会影响MRD监测的灵敏度,...
而固定化Panel 监测MRD的突变数量在不同患者中存在较大差异,不同癌种患者突变图谱存在较大差异,相同癌种不同患者间突变同样存在异质性,CAPP-seq技术采用肺癌Panel,平均每位患者检测到4个突变[1]。综合对比,我们不难发现个体化Panel监测的突变数量往往会优于固定化Panel,而监测的突变数量可能会影响MRD监测的灵敏度,...
艾沐蒽推出的Seq-MRD®血液癌症MRD检测是最早批实现商业化的产品,自2016年研发专利技术至今,艾沐蒽Seq-MRD®已经获得3项国家发明专利: [1]“一种应用于高通量测序检测T细胞白血病微小残留病的引物组合及试剂盒”(专利号: 2016 11204857.0,授权公告号:CN 106957906 B) ...
在中国免疫及靶向治疗高峰论坛暨高博第三届淋巴瘤&骨髓瘤国际高峰论坛上,MAYO CLINIC陈东、Min Shi教授分享了题为“Myeloma MRD Testing”的精彩报告,和与会专家分享骨髓瘤微小残留病灶(MRD)检测的国际经验。博医荟特此整理,以飨读者。...
In contrast, SR patients that are still MRD positive post ASCT tend to have continuing response to treatment and MRD testing only becomes prognostic during maintenance. Of interest is that a high proportion of HR patients that achieve MRD negativity post ASCT and a smaller proportion of MRD ...
We always go for KRAS, EGFR, BRAF out of the blocks if we can and hope that we have a slide or two to do ALK gene rearrangement so just some different balances and nuances in looking at the testing in this environment.Recent Videos Options for MRD Testing Affect Patient Treatment Plan ...
All these results reinforce the role of MRD detection by different strategies in patient prognosis and highlight the use of MRD as an endpoint for multiple myeloma treatment.Similar content being viewed by others Measurable residual disease testing and allogeneic hematopoietic cell transplantation for ...
In this workshop, see how rapid NGS is helping to facilitate swift patient enrollment into a clinical trial aiming to investigate the effectiveness of various therapeutic agents based on genetic testing results. Also, learn how NGS technology is advancing measurable residual disease (MRD) analysis by...